The biological treatment of renal-cell carcinoma and melanoma

Lancet Oncology

Volumn 3, Issue 2, 2002, Pages 89-96

  Nathan, Paul D ^a   Eisen, Tim G ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CISPLATIN; DACARBAZINE; FLUOROURACIL; GANGLIOSIDE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MACROGOL; MEDROXYPROGESTERONE ACETATE; MELANOMA VACCINE; PARACETAMOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; THALIDOMIDE; VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; ANOREXIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CAPILLARY LEAK SYNDROME; CONSTIPATION; CONTROLLED STUDY; DENDRITIC CELL; DEPRESSION; DROWSINESS; DRUG CONJUGATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; IMMUNE RESPONSE; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; TASTE DISORDER; VOMITING;

EID: 0036175516     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00650-2     Document Type: Review

References (88)

1. Survival-based prognostic stratification of 670 patients with advanced renal cell carcinoma treated on successive clinical trials at memorial sloan-kettering cancer center
2. Improved prognostication of renal cell carcinoma using an integrated staging system
3. Cytoreduction nephrectomy in metastatic renal cell cancer., the results of southwest onology group trial 8949
4. A new American joint committee on cancer staging system for cutaneous melanoma
5. Gender and other survival predictors in patient with metastatic melanoma on southwest Oncology Group trials
6. Regression of renal cancer
7. Spontaneous regression of renal cell carcinoma
8. An assessment of the current use of human interferons in therapy of urological cancers
9. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant intenferon alpha and gamma in patients with advanced renal cell carcinoma
10. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up
11. Recombinant leucocyte interferon alpha-Z4 and medroxyprogesterone in advanced renal cell carcinoma
12. Interferon alpha and vinblastine versus medroxypricgesterone acetate in the treatment of metastatic renal cell carcinoma
13. Interferon-alpha and survival in metastatic renal cell carcinoma: Early results of a randomised controlled trial
14. The role of interferon alfa in the treatment of metastatic melanoma
15. Regimens with or without interferon alpha as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials
16. Paraxedne for the prevention of depression induced by high dose interferon alfa
17. Phase I study of polyethylene glycol (PEG) interferon alpha-26 (PEG INTRON) in patients with solid tumors
18. Phase II trial of branchedpeqylated (40kDa) interferon α-2a for patients with advanced renal cell carcinoma (RCC)
19. Aim high-adjuvant interferon in melanoma (high risk): A United Kingdom co-ordinating committee on cancer research (UKCCR) randomised study of observation versus adjuvant low dose extended duration interferon resected malignant melanoma
20. Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials
21. Inteneron alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial 1684
22. Pooled-analysis of four ECOG/Intergroup trials of high-dose Interferon alfa-2b (HDI) In 1916 patients with high-risk resected cutaneous melanoma
23. The role of adjuvant immunotherapy atter radical nephrectomy and prognostic factors in pT3NOMO renal cell carcinoma
24. Adjuvant interferon alpha therapy in renal cell carcinoma (RCQ: Prognostic value of DNA cytophotometry
25. Adjuvant immunotherapy in renal cell carcinoma-comparison of interferon alpha treatment with an untreated control
26. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients
27. Interleukin 2 and lymphokine-activated killer cell therapy of solid tumors, analysis of toxicity and management guidelines
28. Interleukin-2 toxicity
29. Randomised comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
30. High-dose aldesleukin in renal cell carcinoma: Long-term survival update
31. A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (sq) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC)
32. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
33. Combination cytokine therapy: Experimental and clinical trials
34. Recombinant human interleukin-2, recombinant interferon-alpha or both in metastatic renal cell carcinoma
35. The combination of chemotherapy with Il-2 and IFN-A is more active than chemotheraphy or immunotherapy alone in patients with metastatic melanoma: A meta-analysis of 7711 patients with metastatic melanoma
36. Randomised phase III trial of treatment with high dose Interleukin-2 either alone or in combination with interferon alpha 2a in patients with advanced melanoma
37. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer
38. Results of a randomised clinical trial comparing sc Interleukin-2, sc interferon-alpha and bolus iv 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma
39. Protracted venous infusion 5-fluorouracil (PV1 5-FU) in combination with subcutaneous (sc) interleukin-2 (IL-2) and alpha interferon (IFN) in patients with metastatic renal cell cancer: A phase II study
40. Prospective randomised trial of interfferon alfa-2a plus vinblastine versus vinblastine, alone in patients with advanced renal cell cancer
41. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
42. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVQ) and biotherapy using interleukin-2 and interferon-α
43. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
44. Dacarbazine, cisplatin, and interferon alpha with or without interleukin-2 in advanced melanoma: Interim analysis of EORTC trial 18951
45. New approaches to the systemic treatment of melanoma
46. Tumor antigens recognised by T cells
47. MAGE-85, MAGE-B6, MAGE-C2, and MAGE-0. Four new members of the MAGE family with tumor-specific expression
48. Double-blind, placebo-controlled, trial of a shed, polyvalent, melanoma vaccine in stage III melanoma
49. Tumor regressions observed in patients with metastatic melanoma treated with an antgenic peptide encoded by gene MAGE-3 and presented by HLA-A1
50. Active immunotherapy with allogeneic tumour cell vaccines: Present status
51. Preliminary results of a randomised trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases
52. Improved survival in stage III melanoma patients with GM2 antibodies, a randomised trial of adjuvant vaccination with GM2 ganglioside
53. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
54. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma
55. Active specific immunotherapy in patients with renal cell cardnoma (RCC) using autologous tumor derived heat shock protein - Peptide complex 96 (HSPP-96) vaccine
56. Adjuvant immunotherapy treatment of renal carcinoma patients with autolcyous tumor cells and bacillus Calmette-Guenn: Five-year results of a prospective randomised study
57. The use of dendritic cells in cancer therapy
58. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
59. Dendritic cell (DC) therapy for metastatic renal cell carcinoma (mRCC) - A translational phase I clinical trial
60. Immunologic gene therapy of melanoma: Phase I study of therapy with autologous dendritic cells transduced with recombinant adenoviruses encoding melanoma antigens
61. Dendritic cells pulsed with apoptotic tumor cells induce potent antitumor immune response in vitro and in vivo
62. Inpatients with MAGE-1, -3 positive tumors, the injection of autologous dendritIc cells (dc) pulsed with MAGE-1,-3 peptides induces a transient specific induction of blood anti-MAGE-1,-3 T cells that is not improved hemocyanin (klh) used as non-specific help
63. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
64. A phase II study of dendritic cell mobilization with GM-CSF in conjunction with IL-2 as immunotherapy for renal cell carcinoma (RCC) an initial report
65. Combined immunotherapy with subcutaneous GM-CSF, low dose IL-2 and IFNα can induce complete remission in metastatic renal cell carcinoma
66. Characterization of circulating dendritic cells (DC) in metastatic renal carcinoma (RC) patients (pts) following flt-3 ligand (flt-31) treatment with or without interleukin-2
67. The modified group C experience - Phase III randomised trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma
68. Prospective randomised trial of high-dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer
69. Tumor infiltrating lymphocyte therapy (TIL) for metastatic renal cancer (RC) using interleukin-2 (IL-2)
70. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
71. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
72. Thalidomide is an inhibitor of angiogenesis
73. Effect of thalldbmide on tumour necrosis factor production and antitumour activity induced by 5,6-dimethylxantheone-4-acetic acid
74. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
75. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha prodrugs: The role of TNF-alpha downregulation in tumor cell sensitization
76. Dual role of tumor necrosis factor-alpha in angiogenesis
77. Interleukin-6 and renal cell cancer: Production, regulation and growth effects
78. Anticytokine approaches to the treatment of anorexia and cachexia
79. Evidence that tumour necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcaemia, and leukocytosis in a human tumour in nude mice
80. Radomized placebo-controlled clinical trial of high-dose interleukin 2 in combination with a soluble p75 tumor necrosis factor receptor immuncylobulln G chimeta in patients with advanced melanoma and renal cell carcinoma
81. Antitumor activity of thalidomide in refractoty multiple myeloma
82. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
83. Activity of thalidomide in AIDS-related Kaposi's sarcoma
84. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
85. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
86. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, ST1571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-kit (CD117)
87. ST1571, an active drug in metastatic gastrointestinal stromal tumours (GIST), and EORTC phase I study
88. Farnesyl transferase inhibitors: A novel targeted therapy for cancer